1. Home
  2. AMBO vs BCAB Comparison

AMBO vs BCAB Comparison

Compare AMBO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ambow Education Holding Ltd.

AMBO

Ambow Education Holding Ltd.

HOLD

Current Price

$2.38

Market Cap

6.5M

Sector

Real Estate

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.56

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBO
BCAB
Founded
2000
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.4M
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
AMBO
BCAB
Price
$2.38
$3.56
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
51.4K
35.1K
Earning Date
08-05-2025
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
337.04
29.86
EPS
0.01
N/A
Revenue
$9,469,000.00
$300,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$290.54
N/A
Revenue Growth
0.82
N/A
52 Week Low
$1.47
$0.12
52 Week High
$6.75
$6.52

Technical Indicators

Market Signals
Indicator
AMBO
BCAB
Relative Strength Index (RSI) 40.65 49.11
Support Level $1.91 $3.19
Resistance Level $2.56 $5.18
Average True Range (ATR) 0.24 0.33
MACD -0.02 0.01
Stochastic Oscillator 12.12 61.49

Price Performance

Historical Comparison
AMBO
BCAB

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: